ACTG A5324 is a phase IV randomized, double-blinded, placebo-controlled study to assess the efficacy of adding Maraviroc (MVC)...
This is a Phase I, multi-site, open-label, non-comparative study of the PK, safety, tolerability, and acceptability of a...
A major disadvantage of giving SD NVP is the potential for maternal development of NVP resistance and additional resistance to...
Study of MDR TB Cases and Their Household Contacts: Operational Feasibility to Inform PHOENIx Trial Design
The study is being done with people who are taking their first anti-HIV drug regimen (including an Non-Nucleoside Reverse...
